News

Vivus Biopharmaceuticals’ investigative therapy VI-0106 for pulmonary arterial hypertension (PAH) showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial. Pharmacokinetics refers to how a medication is absorbed, distributed, metabolized, and eliminated from the body. VI-0106 is a soft gel formulation of tacrolimus, an immunosuppressant under…

An easy and simple tool called the incremental shuttle walk distance test, or ISWD, appears promising to identify early signs of pulmonary hypertension (PH), according to a new study. The results showed that patients with early PH who don’t show major disease symptoms already have a significant decrease in…

A certain protein found on white blood cells, which plays a role in causing pulmonary arterial hypertension (PAH), may be a potential new therapeutic target, a study in mice and humans suggests. The study, “Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice,” was published…

Exercise has a wide range of benefits for people with pulmonary hypertension (PH), improving physical capacity and quality of life, among other advantages, according to a recent review study. Researchers emphasize, however, that PH patients should only exercise under the guidance of PH and rehabilitation specialists. The study, “…

Women who have hypertension or preeclampsia, a more severe condition that leads to damage in the internal organs, during pregnancy have a two- to three-fold higher risk of developing hypertension later in life. Also, 70 percent of them have higher rates of type 2 diabetes and 30 percent have…

Infusions of large doses of intravenous iron may be a safe treatment approach for patients with low oxygen levels in their blood due to pulmonary hypertension (PH) and/or congenital heart disease (CHD), a study reports. The study, “Use of intravenous iron in cyanotic patients with congenital heart disease…

Roivant recently announced the launch of two new business units, Roivant Pharma and Roivant Health, as well as the creation of Altavant Sciences, a company that will focus on developing new therapies, including RVT-1201 as a potential treatment for pulmonary arterial hypertension (PAH). As part of its long-term strategy, Roivant…

Surgery to remove blood clots from the arteries improves pulmonary hypertension (PH) symptoms but not underlying sleep disorders in patients with chronic thromboembolic pulmonary hypertension (CTEPH), according to a study. The study, “Chronic thromboembolic pulmonary hypertension: Reversal of pulmonary hypertension but not sleep-disordered breathing following…

Larger pulmonary hypertension (PH) registries are needed to advance knowledge about this disease and improve patient care, a new study emphasizes. The report outlines data from a Latvian PH registry and compares it with registries across Europe — and recommends combining registries. With internet access now common and worldwide, patient…

A type of extracorporeal membrane oxygenation (ECMO), a life support technique used to oxygenate the blood, was seen to significantly improve survival in end-stage pulmonary hypertension (PH) and interstitial lung disease (ILD) patients awaiting lung transplants, a retrospective study suggests. Researchers found that when performed in a venoarterial,…

For pulmonary hypertension patients, medications they are taking can influence the severity of their fatigue, a common but often unaddressed symptom of the disease, a study suggests. Findings were published in the study, “Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors,” in the journal European…

Apelin, a peptide naturally produced in the body, reduces resistance in the pulmonary vascular system (blood vessels) and improves cardiac function in patients with pulmonary arterial hypertension (PAH), results from a clinical trial show. The therapy’s effects were even greater in patients also taking PAH medication, especially those on…